|
 |
|
Monoclonal antibody development for metastatic solid tumors treatment
|
The murine monoclonal antibody against secretory HSP90a, secreted by solid tumor with hypoxic core, are quite promising for cancer therapy due to specificity and effectiveness of reducing tumor size. Humanization is required before clinical trial.
|
 |
Required Amount |
$500,000 |
Minimum Investment |
$100,000 |
Region |
Pennsylvania |
Industry 1 |
Biotechnology & Life Sciences |
Industry 2 |
Medical, Pharmaceuticals & Health Care |
Stage |
Pre-Startup/R&D |
Investor Role |
Any |
Amount Invested |
$100,000 |
Investment Reason |
Research & Development |
|
|
|
|
You might be interested in these similiar proposals: |
|
Click here to register as an investor to get more information on this and other business proposals in United States and abroad, or login above if you already
have an account.
Click her to register as an entrepreneur and submit an investment proposal for consideration by investors in United States and abroad, or login above if you already have an account.
|
|
 |
|